Oligohydrosis and Hyperthermia: Pilot Study of a Novel Topiramate Adverse Effect

Abstract

A 6-year-old boy with partial complex seizures developed recurrent episodes of hyperthermia 2 months after topiramate was introduced into his antiepilepsy drug regimen. Further investigation revealed that the febrile episodes were related to environmental temperature and physical activity. A pilocarpine iontophoresis sweat test showed that the amount of sweat produced by the child was 5% that of age-matched controls. Topiramate discontinuation resulted in the disappearance of febrile episodes and normalization of sweat quantity in repeat sweat testing. Based on this observation and the previous data on zonisamide and isolated case reports on topiramate-related hyperthermia and the effect on sweat production, topiramate was suspected of causing oligohydrosis. A pilot study was carried out involving 13 additional children and young adults (age range 1—37 years) receiving topiramate. All patients were directly questioned regarding symptoms of decreased sweating and heat intolerance, went through a pilocarpine iontophoresis sweat test, and were compared with 14 age-matched controls who went through the sweat test for unrelated reasons. Nine of the patients were found to have reduced sweat quantity on the pilocarpine iontophoresis sweat test (including index case) (mean 0.089 g/30 minutes, SD 0.082; age-matched control: mean 0.21 g/30 minutes, SD 0.06). Eight of them were children (below 16 years). However, only three patients revealed symptoms related to heat intolerance. Topiramate is most likely responsible for decreased sweat production as detected by a pilocarpine iontophoresis sweat test. The effect seems to be more significant in children than in adults. There is a discrepancy between test results and clinical symptoms. Interestingly, oligohydrosis was found to be a relatively common side effect of zonisamide. Both zonisamide and topiramate share a carbonic anhydrase inhibitor activity. The significance of oligohydrosis in hot climates should not be underestimated. Its extent, the role of sweat test prediction, and clinical significance during topiramate treatment should be further estimated. (J Child Neurol 2003;18:254—257).

Get full access to this article

View all access options for this article.

References

Glauser TA : Topiramate. Epilepsia 1999;40(Suppl 5):S71—S80.

Wilner A. , Raymond K. , Pollard R. : Topiramate and metabolic acidosis. Epilepsia 1999;40:792—795.

Takeoka M. , Holmes GL , Thiele E. , et al: Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;42:387—392.

Rhee DJ , Goldberg MJ , Parrish RK : Bilateral angle-closed glaucoma and ciliary body swelling from topiramate . Arch Ophthalmol 2001;119:1721—1723.

Sankar PS , Pasquale LR , Grosskreutz CL : Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol 2001;119:1210—1211.

Arcas J. , Ferrer T. , Roche MC , et al: Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42:1363—1365.

Barrera NM , Nieto J. , Nez M. , et al: Anhydrosis and hyperthermia associated with treatment with topiramate . Rev Neurol 2002;34:114—116.

Gibson LE , Cooke RE : A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas using pilocarpine iontophoresis. Pediatrics 1959;23:545—549.

Goldsmith AL : Biology of eccrine and apocrine sweat glands , in Freeberg IM , Eisen AZ , Wolff K , et al (eds): Fitzpatrick's Dermatology in General Medicine, ed 5. Vol. 1. New York, McGraw-Hill, 1999:155—163.

10.

Sato K. , Kang WH , Saga K. , Sato KT : Biology of sweat glands and their disorders. J Am Acad Dermatol 1989;20:537—562.

11.

Briggman JV , Tashian RE , Spicer SS : Immunohistochemical localization of carbonic anhydrase I and II in eccrine sweat glands from control subjects and patients with cystic fibrosis. Am J Pathol 1983;112:250—257.

12.

Noda Y. , Oosumi H. , Morishima T. , et al: Immunohistochemical study of carbonic anhydrase in mixed tumors and adenomas of sweat and sabeceous glands. J Cutan Pathol 1987;4:285—290.

13.

Dahlborn K. , Jansson A. , Nyman S. , et al: Sweat production and localization of carbonic anhydrase in the equine sweat gland during exercise at two ambient temperatures. Equine Vet J Suppl 1999;30:398—403.

14.

Okumura A. , Hayakawa F. , Kuno K. , Watanabe K. : Oligohydrosis caused by zonisamide. No To Hattatsu 1996;28:44—47.

15.

Shimizu T. , Yamashita Y. , Satoi M. , et al: Heat stroke like episode in a child caused by zonisamide. Brain Dev 1997;19:366—368.

16.

Okumura A. , Ishihara N. , Kato T. , et al: Predictive value of acetylcholine stimulation testing for oligohydrosis caused by zonisamide. Pediatr Neurol 2000; 23: 59—61.

17.

Dodgson SJ , Shank RP , Maryanoff BE : Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35—S39.

18.

Leppik IL : Zonisamide. Epilepsia 1999;40(Suppl 5):S23—S29.

19.

Imai K. , Mano T. , Shimono K. , et al: Three cases of hypoactivity and poor appetite with zonisamide-induced metabolic acidosis. No To Hattatsu 2000;32:75—77.

20.

White HS : Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs, review. Epilepsia 1999;40(Suppl 5):S2—S10.